The Directorate of Health Services (DHS) in Goa has extended its partnership with AstraZeneca and Qure.ai for the Early Lung Cancer Detection Program, aimed at improving early diagnosis and treatment outcomes. The MoU was signed in the presence of Health Minister Vishwajit Rane, marking a two-year extension of the initiative.
Back
Launched in June 2024, the program uses Qure.ai's artificial intelligence (AI) technology to screen chest X-rays for signs of lung cancer. Since its introduction, over 33,800 X-rays have been screened across 17 DHS centres, identifying 3,144 nodules, including 143 classified as high-risk. One confirmed lung cancer case has been detected through the program's referral system, involving physician reviews, CT scans, and biopsies.
Goa Health Minister, Vishwajit Rane emphasized the importance of early detection in reducing cancer-related deaths. "With the successful deployment of AI-powered tools, we are witnessing faster diagnosis and improved referrals. This partnership reinforces our commitment to preventive healthcare and enhancing Goa's public health system," he said.
Patients undergoing X-rays will now be mandatorily screened for lung cancer as part of the process at govt. hospitals.
The program also features Nurse Navigators who support high-risk patients, ensuring follow-up from screening to diagnosis. A strong referral network involving physicians, specialists, and diagnostic facilities has been established to streamline clinical interventions.
The extended partnership aims to expand screening efforts, improve patient tracking, and introduce new training modules for healthcare workers at DHS centres.
